Filtered By:
Vaccination: Ebola Vaccine
This page shows you your search results in order of date. This is page number 13.
Order by Relevance | Date
Total 607 results found since Jan 2013.
The efficient development of a novel recombinant adenovirus zoster vaccine perfusion production process
This study demonstrates the perfusion process to be superior strategy for adenovirus-based vaccine production compared to the batch-mode strategy (1,467 IFU/cell). Furthermore, our PATFP system shows potential to be comparable to the XCell ATF® system, and it would become an alternative perfusion strategy for the vaccine production.PMID:35216843 | PMC:PMC8863426 | DOI:10.1016/j.vaccine.2022.02.024
Source: Vaccine - February 26, 2022 Category: Allergy & Immunology Authors: Jianqi Nie Yang Sun Kai Feng Lingling Huang Ye Li Zhonghu Bai Source Type: research
Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations - United States, 2021
MMWR Morb Mortal Wkly Rep. 2022 Feb 25;71(8):290-292. doi: 10.15585/mmwr.mm7108a2.ABSTRACTOn December 19, 2019, the Food and Drug Administration (FDA) approved rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO, Merck) for the prevention of Ebola virus disease (EVD) caused by infection with Ebola virus, species Zaire ebolavirus, in adults aged ≥18 years. In February 2020, the Advisory Committee on Immunization Practices (ACIP) recommended preexposure vaccination with ERVEBO for adults aged ≥18 years in the United States who are at highest risk for potential occupational exposure to Ebola virus because they are responding to an out...
Source: MMWR Morb Mortal Wkl... - February 24, 2022 Category: Epidemiology Authors: Jason H Malenfant Allison Joyce Mary J Choi Caitlin M Cossaboom Amy N Whitesell Brian H Harcourt Robert L Atmar Julie M Villanueva Beth P Bell Christine Hahn Jamie Loehr Richard T Davey Armand Sprecher Colleen S Kraft Trevor Shoemaker Joel M Montgomery Ri Source Type: research
The ring vaccination trial design for the estimation of vaccine efficacy and effectiveness during infectious disease outbreaks
We describe the application of the design to estimate the efficacy and effectiveness of an Ebola vaccine during the 2014-2016 West African Ebola epidemic. The design has several notable statistical features. Because vaccination occurs around the time of exposure, the design is particularly sensitive to the choice of per protocol analysis period. If incidence wanes before the per protocol analysis period begins (due to a slow-acting vaccine or a fast-moving pathogen), power can be substantially reduced. Mathematical modeling is valuable for exploring the suitability of the approach in different disease settings. Another sta...
Source: Clinical Trials - January 21, 2022 Category: Research Authors: Natalie E Dean Ira M Longini Source Type: research
TWiV 854: Omicron is evasive
TWiV reviews findings that increased fitness of the Omicron variant is due to immune evasion, not an increase in intrinsic transmissibility, and determination of infectious viral load in patients infected with wild type, Delta and Omicron viruses reveals lack of correlation with RNA loads determined by RT-PCR, similar levels of shedding among Delta and Omicron, and greatly reduced shedding in vaccinated people. Hosts: Vincent Racaniello, Dickson Despommier, Rich Condit, Kathy Spindler, and Brianne Barker Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Travel Awa...
Source: This Week in Virology - MP3 Edition - January 16, 2022 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
Immune interference revisited: Impact of live-attenuated influenza vaccine prior to yellow fever vaccination
CONCLUSIONS: In this healthy, young adult military population, there was high seroconversion following YF17D when administered simultaneously and at various time points after LAIV. Slight decreases in seroresponse were seen in women and those receiving YF17D 7-21 days following LAIV.PMID:35031146 | DOI:10.1016/j.vaccine.2021.12.031
Source: Vaccine - January 15, 2022 Category: Allergy & Immunology Authors: Dana M Blyth Zhaodong Liang Maya Williams Clinton K Murray Source Type: research
Ebola virus disease: Current perception of clinical features, diagnosis, pathogenesis, and therapeutics
Acta Virol. 2021;65(4):350-364. doi: 10.4149/av_2021_409.ABSTRACTZoonotic transmission of highly pathogenic viruses, are a cause of deadly epidemics around the globe. These are of particular concern as evident from the recent global pandemic due to Coronavirus disease 2019 (COVID-19). The genus Ebolavirus belongs to the Filoviridae family and its members are known to cause the Ebola virus disease (EVD), a highly contagious disease with a mortality rate of approximately 90%. The similarity of the clinical symptoms to those of various tropical ailments poses a high risk of misdiagnosis. Diagnostic strategies currently utiliz...
Source: Acta Virologica - January 3, 2022 Category: Infectious Diseases Authors: Ruqaiyyah Siddiqui Simal Khan Naveed Ahmed Khan Source Type: research
